SG11201809908TA - Stabilized glycopeptide antibiotic formulations - Google Patents

Stabilized glycopeptide antibiotic formulations

Info

Publication number
SG11201809908TA
SG11201809908TA SG11201809908TA SG11201809908TA SG11201809908TA SG 11201809908T A SG11201809908T A SG 11201809908TA SG 11201809908T A SG11201809908T A SG 11201809908TA SG 11201809908T A SG11201809908T A SG 11201809908TA SG 11201809908T A SG11201809908T A SG 11201809908TA
Authority
SG
Singapore
Prior art keywords
international
avenija
zagreb
pct
formulations
Prior art date
Application number
SG11201809908TA
Other languages
English (en)
Inventor
Sabina Keser
Ivona Jasprica
Jerome Le-Cunff
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of SG11201809908TA publication Critical patent/SG11201809908TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201809908TA 2016-05-09 2017-05-04 Stabilized glycopeptide antibiotic formulations SG11201809908TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662333357P 2016-05-09 2016-05-09
PCT/EP2017/060653 WO2017194385A1 (en) 2016-05-09 2017-05-04 Stabilized glycopeptide antibiotic formulations

Publications (1)

Publication Number Publication Date
SG11201809908TA true SG11201809908TA (en) 2018-12-28

Family

ID=58745200

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809908TA SG11201809908TA (en) 2016-05-09 2017-05-04 Stabilized glycopeptide antibiotic formulations

Country Status (19)

Country Link
US (1) US10729708B2 (cg-RX-API-DMAC7.html)
EP (1) EP3454883A1 (cg-RX-API-DMAC7.html)
JP (1) JP6946343B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190005940A (cg-RX-API-DMAC7.html)
CN (1) CN109069580A (cg-RX-API-DMAC7.html)
AR (1) AR109454A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017262943B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018072948A2 (cg-RX-API-DMAC7.html)
CL (1) CL2018003147A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018011701A2 (cg-RX-API-DMAC7.html)
EA (1) EA201892413A1 (cg-RX-API-DMAC7.html)
IL (1) IL262796A (cg-RX-API-DMAC7.html)
JO (2) JOP20170111B1 (cg-RX-API-DMAC7.html)
MX (1) MX388732B (cg-RX-API-DMAC7.html)
SA (1) SA518400392B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201809908TA (cg-RX-API-DMAC7.html)
TW (2) TWI769694B (cg-RX-API-DMAC7.html)
UY (1) UY37233A (cg-RX-API-DMAC7.html)
WO (1) WO2017194385A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071495A1 (en) 2014-11-06 2016-05-12 Xellia Pharmaceuticals Aps Glycopeptide compositions
WO2021231361A1 (en) * 2020-05-11 2021-11-18 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing active metabolites of remdesivir for inhalation
WO2022031830A1 (en) * 2020-08-04 2022-02-10 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CN115804832B (zh) * 2021-09-14 2026-06-16 海南普利制药股份有限公司 一种万古霉素水溶液组合物
JPWO2023171588A1 (cg-RX-API-DMAC7.html) * 2022-03-08 2023-09-14
US20250295727A1 (en) * 2022-04-26 2025-09-25 Hikma Pharmaceuticals Usa Inc. Stable, ready-to-administer aqueous formulations of dalbavancin
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
CN117618338A (zh) * 2022-08-16 2024-03-01 海南普利制药股份有限公司 一种稳定的奥利万星药物水溶液及其制备方法
AU2023359653A1 (en) * 2022-10-12 2025-05-29 Hikma Pharmaceuticals Usa Inc. Liquid dalbavancin composition
UY40482A (es) * 2022-10-12 2024-04-30 Hikma Pharmaceuticals Usa Inc Composición líquida de dalbavancina.
EP4431083A1 (en) * 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin
WO2025158262A1 (en) * 2024-01-23 2025-07-31 Lupin Limited Stable pharmaceutical compositions of dalbavancin as ready-to-dilute formulation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1278549A (en) * 1916-12-16 1918-09-10 J E Simmons Nut and bolt lock.
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
US4885275A (en) 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
WO1997019690A1 (en) * 1995-12-01 1997-06-05 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
EP1276759B1 (en) * 2000-05-02 2008-07-30 Theravance, Inc. Reductive alkylation process on glycopeptides
DE60136926D1 (de) * 2000-05-02 2009-01-22 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
WO2001083520A2 (en) * 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
AU2001267011B2 (en) * 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
WO2005042584A2 (en) * 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
EP1848413B1 (en) 2005-02-14 2014-04-09 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
US8518873B2 (en) 2007-09-12 2013-08-27 The Medicines Company Method of inhibiting clostridium difficile by administration of oritavancin
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CN102755629A (zh) * 2012-08-02 2012-10-31 上海瑞创医药科技有限公司 与万古霉素形成抗菌增效包合物的组分和制备方法及其应用
CA2891487A1 (en) * 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9616098B2 (en) 2013-05-30 2017-04-11 Scidose, Llc Formulations of vancomycin
WO2016071495A1 (en) * 2014-11-06 2016-05-12 Xellia Pharmaceuticals Aps Glycopeptide compositions
EA036750B1 (ru) 2016-01-08 2020-12-16 Гуфик Байосайенсиз Лимитед Лиофилизированная парентеральная композиция тигециклина и способ ее приготовления
CA3014294A1 (en) * 2016-02-18 2017-08-24 Melinta Therapeutics, Inc. Oritavancin formulations

Also Published As

Publication number Publication date
JOP20220039A1 (ar) 2023-01-30
CN109069580A (zh) 2018-12-21
MX388732B (es) 2025-03-20
SA518400392B1 (ar) 2022-05-09
EP3454883A1 (en) 2019-03-20
CO2018011701A2 (es) 2019-02-08
KR20190005940A (ko) 2019-01-16
TW201740955A (zh) 2017-12-01
MX2018013584A (es) 2019-04-01
WO2017194385A1 (en) 2017-11-16
IL262796A (en) 2018-12-31
US10729708B2 (en) 2020-08-04
AU2017262943A1 (en) 2018-11-22
TW202133875A (zh) 2021-09-16
JP2019518733A (ja) 2019-07-04
TWI769694B (zh) 2022-07-01
AU2017262943B2 (en) 2020-05-14
CA3021935A1 (en) 2017-11-16
UY37233A (es) 2018-01-02
JP6946343B2 (ja) 2021-10-06
BR112018072948A2 (pt) 2019-02-19
CL2018003147A1 (es) 2018-12-28
US20190175632A1 (en) 2019-06-13
AR109454A1 (es) 2018-12-12
EA201892413A1 (ru) 2019-05-31
JOP20170111B1 (ar) 2022-03-15
TWI772296B (zh) 2022-08-01

Similar Documents

Publication Publication Date Title
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201807912SA (en) Vaccine against rsv
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201811416VA (en) Crystalline solid forms of a bet inhibitor
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201901986SA (en) Process for the manufacture of a solid pharmaceutical adminstration form
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201807023QA (en) Compositions and methods for preventing and/or treating vitamin b12 deficiency